Xeris Biopharma to Report Fourth Quarter and Full-Year 2024 Financial Results on March 6, 2025
Xeris Biopharma Holdings (Nasdaq: XERS) has announced it will release its fourth quarter and full-year 2024 financial results before U.S. markets open on March 6, 2025. The company will also provide 2025 financial guidance during this release.
Management will host a conference call and webcast at 8:30 a.m. Eastern Time on the same day. The company currently has three commercially available products: Recorlev® for endogenous Cushing's syndrome, Gvoke® for severe hypoglycemia treatment, and Keveyis® for primary periodic paralysis. Their pipeline includes XP-8121, a Phase 3-ready, once-weekly subcutaneous injection for hypothyroidism, along with early-stage programs utilizing their XeriSol® and XeriJect® technology platforms.
Xeris Biopharma Holdings (Nasdaq: XERS) ha annunciato che rilascerà i suoi risultati finanziari del quarto trimestre e dell'intero anno 2024 prima dell'apertura dei mercati statunitensi il 6 marzo 2025. L'azienda fornirà anche indicazioni finanziarie per il 2025 durante questo rilascio.
La direzione ospiterà una conferenza telefonica e una diretta web alle 8:30 ora orientale dello stesso giorno. Attualmente, l'azienda ha tre prodotti commercialmente disponibili: Recorlev® per la sindrome di Cushing endogena, Gvoke® per il trattamento dell'ipoglicemia grave e Keveyis® per la paralisi periodica primaria. Il loro pipeline include XP-8121, un'iniezione sottocutanea pronta per la fase 3, da somministrare una volta a settimana per l'ipotiroidismo, insieme a programmi in fase iniziale che utilizzano le loro piattaforme tecnologiche XeriSol® e XeriJect®.
Xeris Biopharma Holdings (Nasdaq: XERS) ha anunciado que publicará sus resultados financieros del cuarto trimestre y del año completo 2024 antes de la apertura de los mercados en EE. UU. el 6 de marzo de 2025. La compañía también proporcionará orientación financiera para 2025 durante este anuncio.
La gerencia llevará a cabo una conferencia telefónica y una transmisión web a las 8:30 a.m. hora del Este el mismo día. Actualmente, la empresa tiene tres productos comercialmente disponibles: Recorlev® para el síndrome de Cushing endógeno, Gvoke® para el tratamiento de la hipoglucemia severa y Keveyis® para la parálisis periódica primaria. Su cartera incluye XP-8121, una inyección subcutánea lista para fase 3, que se administra una vez a la semana para el hipotiroidismo, junto con programas en etapas iniciales que utilizan sus plataformas tecnológicas XeriSol® y XeriJect®.
Xeris Biopharma Holdings (Nasdaq: XERS)는 2024년 4분기 및 연간 재무 결과를 미국 시장이 열리기 전에 2025년 3월 6일에 발표할 것이라고 발표했습니다. 회사는 이 발표에서 2025년 재무 가이드라인도 제공할 예정입니다.
경영진은 같은 날 동부 표준시로 오전 8시 30분에 전화 회의 및 웹캐스트를 진행할 것입니다. 현재 이 회사는 세 가지 상업적으로 이용 가능한 제품을 보유하고 있습니다: Recorlev®는 내인성 쿠싱 증후군을 위한 것이고, Gvoke®는 중증 저혈당 치료를 위한 것이며, Keveyis®는 원발성 주기성 마비를 위한 것입니다. 그들의 파이프라인에는 XP-8121, 즉 저혈증을 위한 주 1회 피하 주사제인 3상 준비가 되어 있으며, XeriSol® 및 XeriJect® 기술 플랫폼을 활용한 초기 단계 프로그램도 포함되어 있습니다.
Xeris Biopharma Holdings (Nasdaq: XERS) a annoncé qu'elle publiera ses résultats financiers du quatrième trimestre et de l'année 2024 avant l'ouverture des marchés américains le 6 mars 2025. L'entreprise fournira également des prévisions financières pour 2025 lors de cette annonce.
La direction organisera une conférence téléphonique et un webinaire à 8h30, heure de l'Est, le même jour. Actuellement, l'entreprise propose trois produits commercialement disponibles : Recorlev® pour le syndrome de Cushing endogène, Gvoke® pour le traitement de l'hypoglycémie sévère et Keveyis® pour la paralysie périodique primaire. Leur pipeline inclut XP-8121, une injection sous-cutanée prête pour la phase 3, à administrer une fois par semaine pour l'hypothyroïdie, ainsi que des programmes en phase précoce utilisant leurs plateformes technologiques XeriSol® et XeriJect®.
Xeris Biopharma Holdings (Nasdaq: XERS) hat angekündigt, dass es seine Finanzergebnisse für das vierte Quartal und das gesamte Jahr 2024 vor der Eröffnung der US-Märkte am 6. März 2025 veröffentlichen wird. Das Unternehmen wird auch Finanzprognosen für 2025 während dieser Veröffentlichung bereitstellen.
Das Management wird am selben Tag um 8:30 Uhr Eastern Time eine Telefonkonferenz und einen Webcast veranstalten. Das Unternehmen hat derzeit drei kommerziell erhältliche Produkte: Recorlev® für das endogene Cushing-Syndrom, Gvoke® zur Behandlung schwerer Hypoglykämie und Keveyis® für primäre periodische Lähmung. Ihre Pipeline umfasst XP-8121, eine für Phase 3 bereitstehende, einmal wöchentliche subkutane Injektion gegen Hypothyreose, sowie Programme in der Frühphase, die ihre Technologieplattformen XeriSol® und XeriJect® nutzen.
- None.
- None.
Conference call and webcast at 8:30am ET
To pre-register for the call, please go to the following link: https://www.netroadshow.com/events/login?show=ecd4fc1e&confId=76382
After registering, a confirmation email will be sent, including dial-in details and a unique code for entry. The Company recommends registering a minimum of ten minutes prior to the start of the call. Following the conference call, a replay will be available until Thursday, March 20, 2025 at US:1 929 458 6194, US Toll Free: 1 866 813 9403,
To join the webcast, please visit “Events” on investor relations page of the Company’s website at www.xerispharma.com or use this link: https://events.q4inc.com/attendee/959090782
Xeris Biopharma Holdings, Inc.
Xeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products: Recorlev®, for the treatment of endogenous Cushing’s syndrome; Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis®, a proven therapy for primary periodic paralysis. Xeris also has a pipeline of development programs led by XP-8121, a Phase 3-ready, once-weekly subcutaneous injection for hypothyroidism, as well as multiple early-stage programs leveraging Xeris’ technology platforms, XeriSol® and XeriJect®, for its partners.
Xeris Biopharma Holdings is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250227136020/en/
Investor Contact
Allison Wey
Senior Vice President, Investor Relations and Corporate Communications
awey@xerispharma.com
Source: Xeris Biopharma Holdings, Inc.
FAQ
When will Xeris Biopharma (XERS) release its Q4 and full-year 2024 results?
What products are currently in Xeris Biopharma's (XERS) commercial portfolio?
What is Xeris Biopharma's (XERS) lead pipeline candidate?
How can investors access Xeris Biopharma's (XERS) Q4 2024 earnings call?
